Postpartum Depression Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight

DelveInsight's Postpartum Depression Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Postpartum Depression Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Postpartum Depression Market report covers emerging drugs, current treatment practices, market share of individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Postpartum Depression Overview
Postpartum depression (PPD) is a serious health issue that can affect about 15% of the female population after giving birth. It often conveys significant negative consequences to the offspring. The symptoms and risk factors are somewhat similar to those found in non-postpartum depression. The main difference resides in the fact that PPD is triggered by postpartum specific factors, including especially biological changes in hormone levels. Patients are usually diagnosed using a questionnaire onsite or in a clinic. Treatment of PPD often involves psychotherapy and antidepressant medications.

Download a sample copy of the report @ https://www.delveinsight.com/sample-request/postpartum-depression-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Key highlights of the Postpartum Depression Market Report
• The total diagnosed prevalent population of Postpartum Depression in the United States was 621,340 in 2020.
• In the United States, the total diagnosed prevalent population of Postpartum Depression is estimated to increase at a CAGR of 0.60%, during the study period 2018-2030.
• DelveInsight has also made analysis on the various types of depression that occur post pregnancy such as Baby Blues, Postpartum Psychosis, Postpartum OCD, Posttraumatic stress disorder (PTSD) and Postpartum Panic Disorder. In the United States, the number of cases of these disorders were 2,067,000, 62,010, 206,700, 413,400 and 289,380, respectively in 2020.

Postpartum Depression Market
The Postpartum Depression market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Postpartum Depression Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Postpartum Depression Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Postpartum Depression Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Postpartum Depression Therapeutic Market
Postpartum Depression is managed through several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. It can be treated with antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy. The current US Postpartum Depression therapeutics market consists of only one FDA-approved product-Zulresso (brexanolone/SAGE-547)-to treat patients with PPD. The drug is an asset of Sage Therapeutics and was approved by the US FDA in March 2019. The therapy has transformed the treatment landscape of PPD without putting the newborn at risk of any side effects.

Postpartum Depression Market Forecast
DelveInsight estimates that the outlook of the Postpartum Depression market is anticipated to change in the next decade owing to a better understanding of mental health disorders, discovery of new upcoming therapeutic strategies harnessing the principle of GABAA receptor modulation, improvements in research and development, entry of novel therapies and an influx of pharma companies during the forecast period of 2021-2030. Pharmaceutical companies such as Sage Therapeutics, Marinus Pharma and others are proactively developing therapies to push the Postpartum Depression market share growth and manufacture novel therapies to transform the treatment paradigm of the Postpartum Depression therapeutics market.

Request a sample copy of the market report @ https://www.delveinsight.com/sample-request/postpartum-depression-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Postpartum Depression Market Drugs
Zulresso (brexanolone): Sage Therapeutics
Zulresso marketed by Sage Therapeutics is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. Brexanolone was granted a priority review and was designated a breakthrough treatment by the FDA. Brexanolone is available to the patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. It is important to note that Zulresso (brexanolone) is the first drug approved by the US FDA specifically for postpartum depression in adults. Zulresso has also been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of PPD.

Postpartum Depression Emerging Drugs

Zuranolone (SAGE-217): Sage Therapeutics
Zuranolone (SAGE-217) by Sage Therapeutics is an investigational, oral, novel medicine in development for postpartum depression. It is given once-daily; a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), which contributes in regulating CNS function significantly.

Ganaxolone (CCD-1042): Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited antiepileptic (anti-seizure), anxiolytic (anti-anxiety), and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (intravenous, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors.

Postpartum Depression Market Outlook
According to the American Psychiatric Association (APA), Postpartum depression (PPD) is a serious, but treatable medical illness, which involves feelings of extreme sadness, emotional liability, indifference and/or anxiety, as well as changes in energy, sleep, and appetite, and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months. In more severe cases, it can develop into chronic episodes of depression.

Postpartum Depression Treatment Market
Treatments include the antidepressant medications along with the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments, as well as non-pharmacologic treatments. Besides, the medical care of a PDD patient and his family is incomplete without providing a support system for their psychosocial wellbeing. The current US market consists of only one approved product-Zulresso (brexanolone/SAGE-547)-to treat patients with PPD.

Check out for more information @ https://www.delveinsight.com/report-store/postpartum-depression-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Postpartum Depression Epidemiology
The epidemiology section covers insights into the historical and current Postpartum Depression Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Postpartum Depression Market Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression Market or expected to get launched in the market during the study period. The analysis covers Postpartum Depression market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Postpartum Depression Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Postpartum Depression include therapies that are oral, anthracycline sparing and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.

Postpartum Depression Market Companies
• Sage Therapeutics, and several others
Explore more information about the report @ https://www.delveinsight.com/report-store/postpartum-depression-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insight
2. Market Overview at a Glance
3. Disease Background and Overview
4. Epidemiology and Patient Population
5. Country-Wise Epidemiology of Postpartum Depression (PPD)
6. Treatment
7. Treatment Algorithm by American Family Physician (AFP)
8. Treatment Guidelines by Unicare
9. Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)
10. Recognized Establishments
11. Unmet Needs
12. Marketed Profile
13. Postpartum Depression: 7 Major Market Analysis
14. The United States Market Outlook
15. Japan: Market Outlook
16. KOL Reviews
17. Case Reports
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

Connect with our Business Development Consultant @ https://www.delveinsight.com/report-store/postpartum-depression-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.